Inhibition and reversal of platelet aggregation by αIIbβ3 antagonists depends on the anticoagulant and flow conditions: differential effects of Abciximab and Lamifiban
Summary Shear influences platelet aggregate formation and stability, as well as the inhibitory capacities of antithrombotic drugs. We compared the inhibitory and disaggregating properties of two distinct αIIbβ3 antagonists, Abciximab and Lamifiban, on platelet aggregation induced by adenosine diphos...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2005-11, Vol.131 (3), p.348-355 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 355 |
|---|---|
| container_issue | 3 |
| container_start_page | 348 |
| container_title | British journal of haematology |
| container_volume | 131 |
| creator | Frojmovic, Mony Labarthe, Benoit Legrand, Chantal |
| description | Summary
Shear influences platelet aggregate formation and stability, as well as the inhibitory capacities of antithrombotic drugs. We compared the inhibitory and disaggregating properties of two distinct αIIbβ3 antagonists, Abciximab and Lamifiban, on platelet aggregation induced by adenosine diphosphate (ADP) (5 μmol/l) in platelet‐rich plasma (PRP), in an aggregometer (poorly defined low shear, |
| doi_str_mv | 10.1111/j.1365-2141.2005.05782.x |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_17196685</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>BJH5782</sourcerecordid><originalsourceid>FETCH-LOGICAL-p2042-c385b84ee9b0eb670c2bb04f3caac6c9eff1356315910a75b81134687a5e34db3</originalsourceid><addsrcrecordid>eNpFUUFu2zAQJIoUiJPmD7z0KGUpipIcIAfXaGsHBnppz8SSWik0FEkQ1dp-Uo_JQ_KmUnLQ8MIBZnZmscMYFxCL8G73sZCZihKRijgBUDGovEji4we2-E9csAUA5JGAtLhkV97vAYQEJRbs77Z9dMaNrms5tiUf6A8NHhveVbxvcKSGRo51PVCNs8ic-OvzdmteX2QYGLHuWudHz0vqqS09D5LxkSbK2Q7r301As3PVdAduu7acw_wdL11V0UBBGOIoYBtsQuzKWHd0T2jmsR0-ucoZbD-xjxU2nm7e_mv269vXn-tNtPvxfbte7aI-gTSJrCyUKVKipQEyWQ42MQbSSlpEm9llCBJSZVKopQDMg1YImWZFjopkWhp5zT6ffXv0FptqwNY6r_shrDSctMjFMssKFXT3Z93BNXR650FPvei9ns6vp_PrqRc996KP-svDZkLyH50-iIk</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Inhibition and reversal of platelet aggregation by αIIbβ3 antagonists depends on the anticoagulant and flow conditions: differential effects of Abciximab and Lamifiban</title><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><creator>Frojmovic, Mony ; Labarthe, Benoit ; Legrand, Chantal</creator><creatorcontrib>Frojmovic, Mony ; Labarthe, Benoit ; Legrand, Chantal</creatorcontrib><description>Summary
Shear influences platelet aggregate formation and stability, as well as the inhibitory capacities of antithrombotic drugs. We compared the inhibitory and disaggregating properties of two distinct αIIbβ3 antagonists, Abciximab and Lamifiban, on platelet aggregation induced by adenosine diphosphate (ADP) (5 μmol/l) in platelet‐rich plasma (PRP), in an aggregometer (poorly defined low shear, <100/s) and in a microcouette at arterial shear rate (1000/s). Platelet aggregation was detected by changes in light transmission in the aggregometer (TA), and by particle counting with a flow cytometer (PA). Lamifiban (1 μmol/l) completely inhibited TA or PA induced by ADP in citrated PRP in the aggregometer or microcouette. In contrast, Abciximab (2 μmol/l) only partially inhibited PA in the microcouette while blocking both TA and PA in the aggregometer. Moreover, Abciximab did not reverse platelet aggregates formed either in the microcouette or in the aggregometer, whereas Lamifiban caused complete reversal. On the contrary, Abciximab completely inhibited platelet aggregation induced by ADP in hirudin/d‐Phe–Pro–Arg–chloromethylketone PRP in the microcouette. Our results demonstrate a marked dependence of inhibitory capacity of Abciximab on shear conditions, with citrate anticoagulant responsible for the residual aggregation, in contrast to Lamifiban, another αIIbβ3 antagonist interacting with a distinct site on β3.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/j.1365-2141.2005.05782.x</identifier><identifier>CODEN: BJHEAL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>aggregation ; Biological and medical sciences ; Hematologic and hematopoietic diseases ; Medical sciences ; platelet ; shear ; αIIbβ3 antagonists</subject><ispartof>British journal of haematology, 2005-11, Vol.131 (3), p.348-355</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2141.2005.05782.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2141.2005.05782.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27903,27904,45553,45554,46387,46811</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17196685$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Frojmovic, Mony</creatorcontrib><creatorcontrib>Labarthe, Benoit</creatorcontrib><creatorcontrib>Legrand, Chantal</creatorcontrib><title>Inhibition and reversal of platelet aggregation by αIIbβ3 antagonists depends on the anticoagulant and flow conditions: differential effects of Abciximab and Lamifiban</title><title>British journal of haematology</title><description>Summary
Shear influences platelet aggregate formation and stability, as well as the inhibitory capacities of antithrombotic drugs. We compared the inhibitory and disaggregating properties of two distinct αIIbβ3 antagonists, Abciximab and Lamifiban, on platelet aggregation induced by adenosine diphosphate (ADP) (5 μmol/l) in platelet‐rich plasma (PRP), in an aggregometer (poorly defined low shear, <100/s) and in a microcouette at arterial shear rate (1000/s). Platelet aggregation was detected by changes in light transmission in the aggregometer (TA), and by particle counting with a flow cytometer (PA). Lamifiban (1 μmol/l) completely inhibited TA or PA induced by ADP in citrated PRP in the aggregometer or microcouette. In contrast, Abciximab (2 μmol/l) only partially inhibited PA in the microcouette while blocking both TA and PA in the aggregometer. Moreover, Abciximab did not reverse platelet aggregates formed either in the microcouette or in the aggregometer, whereas Lamifiban caused complete reversal. On the contrary, Abciximab completely inhibited platelet aggregation induced by ADP in hirudin/d‐Phe–Pro–Arg–chloromethylketone PRP in the microcouette. Our results demonstrate a marked dependence of inhibitory capacity of Abciximab on shear conditions, with citrate anticoagulant responsible for the residual aggregation, in contrast to Lamifiban, another αIIbβ3 antagonist interacting with a distinct site on β3.</description><subject>aggregation</subject><subject>Biological and medical sciences</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Medical sciences</subject><subject>platelet</subject><subject>shear</subject><subject>αIIbβ3 antagonists</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNpFUUFu2zAQJIoUiJPmD7z0KGUpipIcIAfXaGsHBnppz8SSWik0FEkQ1dp-Uo_JQ_KmUnLQ8MIBZnZmscMYFxCL8G73sZCZihKRijgBUDGovEji4we2-E9csAUA5JGAtLhkV97vAYQEJRbs77Z9dMaNrms5tiUf6A8NHhveVbxvcKSGRo51PVCNs8ic-OvzdmteX2QYGLHuWudHz0vqqS09D5LxkSbK2Q7r301As3PVdAduu7acw_wdL11V0UBBGOIoYBtsQuzKWHd0T2jmsR0-ucoZbD-xjxU2nm7e_mv269vXn-tNtPvxfbte7aI-gTSJrCyUKVKipQEyWQ42MQbSSlpEm9llCBJSZVKopQDMg1YImWZFjopkWhp5zT6ffXv0FptqwNY6r_shrDSctMjFMssKFXT3Z93BNXR650FPvei9ns6vp_PrqRc996KP-svDZkLyH50-iIk</recordid><startdate>200511</startdate><enddate>200511</enddate><creator>Frojmovic, Mony</creator><creator>Labarthe, Benoit</creator><creator>Legrand, Chantal</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope></search><sort><creationdate>200511</creationdate><title>Inhibition and reversal of platelet aggregation by αIIbβ3 antagonists depends on the anticoagulant and flow conditions: differential effects of Abciximab and Lamifiban</title><author>Frojmovic, Mony ; Labarthe, Benoit ; Legrand, Chantal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p2042-c385b84ee9b0eb670c2bb04f3caac6c9eff1356315910a75b81134687a5e34db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>aggregation</topic><topic>Biological and medical sciences</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Medical sciences</topic><topic>platelet</topic><topic>shear</topic><topic>αIIbβ3 antagonists</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Frojmovic, Mony</creatorcontrib><creatorcontrib>Labarthe, Benoit</creatorcontrib><creatorcontrib>Legrand, Chantal</creatorcontrib><collection>Pascal-Francis</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Frojmovic, Mony</au><au>Labarthe, Benoit</au><au>Legrand, Chantal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition and reversal of platelet aggregation by αIIbβ3 antagonists depends on the anticoagulant and flow conditions: differential effects of Abciximab and Lamifiban</atitle><jtitle>British journal of haematology</jtitle><date>2005-11</date><risdate>2005</risdate><volume>131</volume><issue>3</issue><spage>348</spage><epage>355</epage><pages>348-355</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><coden>BJHEAL</coden><abstract>Summary
Shear influences platelet aggregate formation and stability, as well as the inhibitory capacities of antithrombotic drugs. We compared the inhibitory and disaggregating properties of two distinct αIIbβ3 antagonists, Abciximab and Lamifiban, on platelet aggregation induced by adenosine diphosphate (ADP) (5 μmol/l) in platelet‐rich plasma (PRP), in an aggregometer (poorly defined low shear, <100/s) and in a microcouette at arterial shear rate (1000/s). Platelet aggregation was detected by changes in light transmission in the aggregometer (TA), and by particle counting with a flow cytometer (PA). Lamifiban (1 μmol/l) completely inhibited TA or PA induced by ADP in citrated PRP in the aggregometer or microcouette. In contrast, Abciximab (2 μmol/l) only partially inhibited PA in the microcouette while blocking both TA and PA in the aggregometer. Moreover, Abciximab did not reverse platelet aggregates formed either in the microcouette or in the aggregometer, whereas Lamifiban caused complete reversal. On the contrary, Abciximab completely inhibited platelet aggregation induced by ADP in hirudin/d‐Phe–Pro–Arg–chloromethylketone PRP in the microcouette. Our results demonstrate a marked dependence of inhibitory capacity of Abciximab on shear conditions, with citrate anticoagulant responsible for the residual aggregation, in contrast to Lamifiban, another αIIbβ3 antagonist interacting with a distinct site on β3.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><doi>10.1111/j.1365-2141.2005.05782.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2005-11, Vol.131 (3), p.348-355 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_pascalfrancis_primary_17196685 |
| source | Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content |
| subjects | aggregation Biological and medical sciences Hematologic and hematopoietic diseases Medical sciences platelet shear αIIbβ3 antagonists |
| title | Inhibition and reversal of platelet aggregation by αIIbβ3 antagonists depends on the anticoagulant and flow conditions: differential effects of Abciximab and Lamifiban |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T16%3A54%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20and%20reversal%20of%20platelet%20aggregation%20by%20%CE%B1IIb%CE%B23%20antagonists%20depends%20on%20the%20anticoagulant%20and%20flow%20conditions:%20differential%20effects%20of%20Abciximab%20and%20Lamifiban&rft.jtitle=British%20journal%20of%20haematology&rft.au=Frojmovic,%20Mony&rft.date=2005-11&rft.volume=131&rft.issue=3&rft.spage=348&rft.epage=355&rft.pages=348-355&rft.issn=0007-1048&rft.eissn=1365-2141&rft.coden=BJHEAL&rft_id=info:doi/10.1111/j.1365-2141.2005.05782.x&rft_dat=%3Cwiley_pasca%3EBJH5782%3C/wiley_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |